The most common type of non-Hodgkin lymphoma. It includes the most frequently seen morphologic variants which are: diffuse large B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma and ma...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation surrounding B-cell non-Hodgkin lymphoma is limited due to the complexity and variability of the disease. Because this condition affects a diverse population with varying clinical presentations, systematic studies have been challenging. Additionally, the lack of identified genetic factors further complicates comprehensive clinical characterization and understanding.
To navigate your care effectively, seek a hematologist or oncologist with specific expertise in B-cell non-Hodgkin lymphoma. These specialists can provide tailored treatment options and monitor your condition closely. Additionally, consider participating in clinical trials to access new therapies and contribute to research. You can find more information on clinical trials at [ClinicalTrials.gov](https://clinicaltrials.gov). While there are currently no identified patient organizations, connecting with broader cancer support groups may provide valuable resources and community support.
There are several orphan drugs approved for B-cell non-Hodgkin lymphoma, including ibritumomab tiuxetan, rituximab, romidepsin, and Tositumomab. Additionally, there are designated drugs in development such as (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride and Iodine 131-I radiolabeled murine MAb (Lym-1). Currently, there are 1128 active clinical trials available for this condition. You can explore these trials further at [ClinicalTrials.gov](https://clinicaltrials.gov/search?cond=B-cell%20non-Hodgkin%20lymphoma).
Actionable guidance for navigating care for B-cell non-Hodgkin lymphoma
To navigate your care effectively, seek a hematologist or oncologist with specific expertise in B-cell non-Hodgkin lymphoma. These specialists can provide tailored treatment options and monitor your condition closely. Additionally, consider participating in clinical trials to access new therapies and contribute to research. You can find more information on clinical trials at [ClinicalTrials.gov](https://clinicaltrials.gov). While there are currently no identified patient organizations, connecting with broader cancer support groups may provide valuable resources and community support.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding B-cell non-Hodgkin lymphoma is limited due to the complexity and variability of the disease. Because this condition affects a diverse population with varying clinical presentations, systematic studies have been challenging. Additionally, the lack of identified genetic factors further complicates comprehensive clinical characterization and understanding.
To navigate your care effectively, seek a hematologist or oncologist with specific expertise in B-cell non-Hodgkin lymphoma. These specialists can provide tailored treatment options and monitor your condition closely. Additionally, consider participating in clinical trials to access new therapies and contribute to research. You can find more information on clinical trials at [ClinicalTrials.gov](https://clinicaltrials.gov). While there are currently no identified patient organizations, connecting with broader cancer support groups may provide valuable resources and community support.
There are several orphan drugs approved for B-cell non-Hodgkin lymphoma, including ibritumomab tiuxetan, rituximab, romidepsin, and Tositumomab. Additionally, there are designated drugs in development such as (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride and Iodine 131-I radiolabeled murine MAb (Lym-1). Currently, there are 1128 active clinical trials available for this condition. You can explore these trials further at [ClinicalTrials.gov](https://clinicaltrials.gov/search?cond=B-cell%20non-Hodgkin%20lymphoma).
Actionable guidance for navigating care for B-cell non-Hodgkin lymphoma
To navigate your care effectively, seek a hematologist or oncologist with specific expertise in B-cell non-Hodgkin lymphoma. These specialists can provide tailored treatment options and monitor your condition closely. Additionally, consider participating in clinical trials to access new therapies and contribute to research. You can find more information on clinical trials at [ClinicalTrials.gov](https://clinicaltrials.gov). While there are currently no identified patient organizations, connecting with broader cancer support groups may provide valuable resources and community support.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding B-cell non-Hodgkin lymphoma is limited due to the complexity and variability of the disease. Because this condition affects a diverse population with varying clinical presentations, systematic studies have been challenging. Additionally, the lack of identified genetic factors further complicates comprehensive clinical characterization and understanding.
To navigate your care effectively, seek a hematologist or oncologist with specific expertise in B-cell non-Hodgkin lymphoma. These specialists can provide tailored treatment options and monitor your condition closely. Additionally, consider participating in clinical trials to access new therapies and contribute to research. You can find more information on clinical trials at [ClinicalTrials.gov](https://clinicaltrials.gov). While there are currently no identified patient organizations, connecting with broader cancer support groups may provide valuable resources and community support.
There are several orphan drugs approved for B-cell non-Hodgkin lymphoma, including ibritumomab tiuxetan, rituximab, romidepsin, and Tositumomab. Additionally, there are designated drugs in development such as (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride and Iodine 131-I radiolabeled murine MAb (Lym-1). Currently, there are 1128 active clinical trials available for this condition. You can explore these trials further at [ClinicalTrials.gov](https://clinicaltrials.gov/search?cond=B-cell%20non-Hodgkin%20lymphoma).
Actionable guidance for navigating care for B-cell non-Hodgkin lymphoma
To navigate your care effectively, seek a hematologist or oncologist with specific expertise in B-cell non-Hodgkin lymphoma. These specialists can provide tailored treatment options and monitor your condition closely. Additionally, consider participating in clinical trials to access new therapies and contribute to research. You can find more information on clinical trials at [ClinicalTrials.gov](https://clinicaltrials.gov). While there are currently no identified patient organizations, connecting with broader cancer support groups may provide valuable resources and community support.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.